US equities
|
NVDA
$238.61
▲+1.99%
SPCX
$167.26
▲+5.22%
MU
$1,062.89
▼-1.12%
TSLA
$380.47
▲+2.67%
MSFT
$525.74
▲+1.59%
SNDK
$1,707.95
▼-0.70%
INTC
$117.30
▼-1.71%
META
$742.85
▲+2.03%
NVDA
$238.61
▲+1.99%
SPCX
$167.26
▲+5.22%
MU
$1,062.89
▼-1.12%
TSLA
$380.47
▲+2.67%
MSFT
$525.74
▲+1.59%
SNDK
$1,707.95
▼-0.70%
INTC
$117.30
▼-1.71%
META
$742.85
▲+2.03%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Organogenesis Holdings Inc. - Class A
(NQ:
ORGO
)
1.315
-0.015 (-1.13%)
Delayed Quote
Updated: 2:35 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Organogenesis Holdings Inc. - Class A
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
24 Stocks Moving in Thursday's Pre-Market Session
↗
May 27, 2021
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 82% to $3.24 in pre-market trading after the company announced plans to acquire a Alabama refinery and related logistics assets....
Via
Benzinga
Organogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call Transcript
↗
May 11, 2021
ORGO earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Organogenesis Holdings: Q1 Earnings Insights
↗
May 10, 2021
Shares of Organogenesis Holdings (NASDAQ:ORGO) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 143.75% year over...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
May 10, 2021
Gainers Vir Biotechnology (NASDAQ:VIR) sha...
Via
Benzinga
Earnings Scheduled For May 10, 2021
↗
May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report...
Via
Benzinga
Stocks That Hit 52-Week Highs On Friday
↗
April 09, 2021
During the morning session on Friday, 178 stocks hit new 52-week highs. Noteworthy Points: Microsoft (NASDAQ:MSFT) was the largest firm on a market cap basis to set...
Via
Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
↗
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Earnings Outlook for Organogenesis Holdings
↗
May 07, 2021
Organogenesis Holdings (NASDAQ:ORGO) releases its next round of earnings this Monday, May 10. Here is Benzinga's essential guide to Organogenesis Holdings's Q1 earnings report....
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
May 04, 2021
Gainers Obalon Therapeutics (NASDAQ:OBLN)...
Via
Benzinga
Repligen Stock Gets Relative Strength Rating Upgrade With Earnings Due
↗
April 28, 2021
A Relative Strength Rating upgrade for Repligen shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Medical Device Maker Quanterix Sees Relative Strength Rating Rise To 86
↗
April 27, 2021
On Tuesday, Quanterix stock hit an important technical milestone, with its Relative Strength (RS) Rating rising into to 86, up from 80 the day before.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Intraday Session
↗
April 26, 2021
Gainers Reviva Pharmaceuticals (NASDAQ:RVPH) shares rose 72.91% to $7.47 during Monday's regular session. Reviva Pharmaceuticals's stock is trading at a volume of...
Via
Benzinga
Align Technology Nears Buy Point With Earnings Due
↗
April 21, 2021
Align Technology is near a possible buy zone ahead of its next quarterly earnings report, expected on or around April 28.
Via
Investor's Business Daily
Cancer Therapy Novocure Stock Still On A High As It Clears Technical Benchmark
↗
April 21, 2021
Cancer therapy Novocure stock had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday. It's also an IBD 50 member.
Via
Investor's Business Daily
Cancer Therapy Novocure Stock Flashes Renewed Technical Strength
↗
April 14, 2021
Novocure stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 67 to 92.
Via
Investor's Business Daily
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
↗
April 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
